Plus: Profound secures $35 million for preeclampsia research, and Materna Medical completes an oversubscribed Series B3 funding round.
iPremom's €15 million Seed funding round advances the early identification of pregnancy complications, offering clinicians a new tool for predicting and preventing adverse maternal health outcomes. The funding will support clinical validation and commercial rollout of its MaiRa platform, which analyzes early signals of first-trimester pregnancy complications. The broader maternal health sector sees significant investment in innovation, with Profound securing $35 million for preeclampsia research and Materna Medical completing an oversubscribed Series B3 funding round. Five takes inside, plus a quick-hits roundup.
VIA EU-Startups
Spanish molecular diagnostics company iPremom raised €15 million in Seed funding. This funding will support clinical validation and the commercial rollout of its MaiRa platform. The MaiRa platform analyzes early signals of first-trimester pregnancy complications, such as preeclampsia, through blood tests. This development provides femtech investors and clinicians with a new tool for early prediction and prevention of pregnancy complications, impacting 5% to 8% of all pregnancies globally.
Read the full story →
— The Luteal Editorial Team
VIA Sifted
Ipremom raised a €15m seed round. The femtech company focuses on the early detection of pregnancy complications. This funding empowers Ipremom to advance its technology in the maternal health sector.
Read the full story →
— The Luteal Editorial Team
VIA FutureFemHealth
Profound secured $35 million from the Gates Foundation to research preeclampsia, with an initial $20 million directed to biomarker and drug target discovery. Capital F closed its $17 million debut fund targeting the 'female economy', already backing 13 companies. The FDA approved Lisraya (brepocitinib) as the first targeted oral treatment for dermatomyositis, a condition affecting 70% women. Materna Medical completed an oversubscribed Series B3 funding round after a $5 million first close in June.
Read the full story →
— The Luteal Editorial Team
VIA NHS England News
Millions of children and pregnant women are eligible for flu vaccinations starting today through the NHS flu program. This initiative protects families ahead of winter.
Read the full story →
— The Luteal Editorial Team
VIA Contemporary OB/GYN
ACOG recommends COVID-19, RSV, and flu vaccines for pregnant patients for the 2026–27 respiratory season. This guidance informs maternal health providers about immunization protocols.
Read the full story →
— The Luteal Editorial Team